Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly’s personalized diabetes management system, currently in development to advance the treatment of diabetes
| INDIANAPOLIS, Dec. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly’s personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom’s continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management. The agreement with Dexcom builds on Lilly’s efforts to provide a comprehensive system that integrates connected insulin delivery devices, software and analysis to equip people with type 1 and type 2 diabetes and their healthcare providers with personalized information and guidance to help simplify management of their diabetes. “Even with all of the advances in diabetes technology, insulin therapy is still overwhelming and complex,” said Mike Mason, senior vice president, Connected Care and Insulins, Lilly Diabetes. “We’re excited to include Dexcom’s technology in the solutions we deliver to people with diabetes to help improve health outcomes by delivering actionable insights in one connected system. As we integrate our expertise and insights with those from our partners, like Dexcom, we are aiming to not only transform the way we develop and deliver medicine, but to transform how people manage their diabetes.” The personalized diabetes management system being developed will include both pen- and pump-based platforms. The goal of the pen-based platform is to integrate personalized data from a prefilled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application. Personalized data is transferred from the pen via an optional attachment. The goal of the pump-based platform, which is a hybrid-closed loop system, is to use integrated devices – an insulin pump, continuous glucose monitor and a dedicated handheld controller or smartphone application that controls the system – to automate insulin dosing. “CGMs provide people with diabetes and their healthcare team with important real-time data that can help alleviate the burden of diabetes management, including overall glucose level trends and information on time spent in target blood glucose range,” said Rick Doubleday, executive vice president and chief commercial officer of Dexcom. “We’re looking forward to expanding our collaboration with Lilly as we integrate our technology into their system and believe it will help reduce some of the complexity that can come from managing diabetes every day.” About Diabetes About Lilly Diabetes About Eli Lilly and Company About Dexcom, Inc. This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the potential of the personalized diabetes management system for the management and treatment of diabetes, and reflects Lilly’s current beliefs. However, as with any pharmaceutical product or medical device, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there is no guarantee that the connected diabetes solutions will be commercially successful or that the company will meet its anticipated timelines for the roll out of this system. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to:
SOURCE Eli Lilly and Company | ||||||
Company Codes: NYSE:LLY, NASDAQ-NMS:DXCM |
View original content to download multimedia: